Effect of carperitide on plasma adiponectin levels in acute decompensated heart failure patients with diabetes mellitus.
BACKGROUND
It is reported that adiponectin has a cardioprotective effect and is decreased in type 2 diabetes mellitus (DM).


RESULTS
The effect of carperitide (atrial natriuretic peptide: ANP) on plasma adiponectin levels was evaluated in acute decompensated heart failure (ADHF) patients with and without DM. In 47 patients (DM: n=11) who were admitted with ADHF, blood samples were collected before and 7 days after administration of carperitide. The plasma levels of ANP, brain natriuretic peptide (BNP), aldosterone and adiponectin were measured. Plasma adiponectin levels were significantly increased (17.6 +/-1.5 to 19.6 +/-1.8 microg/ml, P=0.0003) concomitant with the increase in ANP and decrease in BNP 7 days after carperitide infusion. Although adiponectin levels before treatment were slightly lower in ADHF patients with DM, the % increase in adiponectin levels was significantly greater in ADHF patients with DM than in those without DM (26.7 vs 6.6%, P=0.007). In the stepwise multivariate analyses, a higher plasma aldosterone levels before treatment (P=0.04) and DM (P=0.01) were significant independent predictors of a greater % increase in adiponectin levels after treatment with carperitide.


CONCLUSIONS
Carperitide infusion increases the plasma adiponectin level, especially in ADHF patients with DM.
Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu, Japan.
Masayuki
M
Yamaji
Takayoshi
T
Tsutamoto
Toshinari
T
Tanaka
Chiho
C
Kawahara
Keizo
K
Nishiyama
Takashi
T
Yamamoto
Masanori
M
Fujii
Minoru
M
Horie
D000208:Acute Disease; D052242:Adiponectin / Q000097:blood; D000368:Aged; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D048909:Diabetes Complications / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007263:Infusions, Parenteral; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010865:Pilot Projects; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D002317:Cardiovascular Agents; C472955:NPPA protein, human; D020097:Natriuretic Peptide, Brain; D000450:Aldosterone; D009320:Atrial Natriuretic Factor